/cloudfront-us-east-1.images.arcpublishing.com/eluniverso/QSB7NLWGXVCC3PITCMNPNT2UIU.jpg "Pfizer prescribes oral medicine to treat COVID-19 | International | Notice")
The clinical trial on this drug is carried out in the United States.
While advancing the vaccine with its dose of dose against the coronavirus, Pfizer Pharmaceuticals announced this March that it has launched a clinical trial to see the effectiveness of a drug that covates COVID-19 and is administered orally.
The study is carried out in the United States, according to information from EFE.
Accord with the laboratory, the medicine, which is called PF-07321332, has been demonstrated in studies in vitro is a “potent inhibitor of antiviral activity against SARS-CoV-2” and other coronaviruses, suggesting its “potential” for treatment with COVID-19 and other “amenazas”.
“We designed PF-07321332 as a potential oral therapy that can be treated with the first signal of infection, without requiring patients to be hospitalized or critically ill,” said the business scientist, Mikael Dol.
There is currently no official treatment for the COVID-19 and the Grand Mayor is in agreement with the Accumulation Experience since the beginning of the pandemic.
In addition, the vaccine is more of a preventative method, which in this case avoids taking COVID-19 seriously, as the drug of a drug that is proven to be an effective treatment against the severe virus helps to control the pandemic more quickly. (I)